Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 10, 2008, Pages 1736-1741

  Wong, Pancras C ^a   Watson, C A ^a   Crain, E J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Apixaban; Arterial thrombosis; Aspirin; Clopidogrel; Direct factor Xa inhibitor; Hemostasis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CUTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HEMOSTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBUS;

ANIMALS; ASPIRIN; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; DRUG THERAPY, COMBINATION; FACTOR XA; FIBRINOLYTIC AGENTS; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; PYRIDONES; RABBITS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 52449130392     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03092.x     Document Type: Article

References (23)

1. 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31: 195-204.
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
3. Eikelboom JW, Weitz JI, Budaj A, Zhao F, Copland I, Maciejewski P, Johnston M, Yusuf S. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2002; 23: 1771-9.
4. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27: 519-26.
5. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-9.
6. Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl -4,5,6,7-tetrahydro -1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, e.cacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Med Chem 2007; 50: 5339-56.
7. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM. Apixaban, an oral, direct and highly selective factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6: 820-9.
8. He K, He B, Grace JE, Xin B, Zhang D, Pinto DJ, Luettgen JM, Knabb RM, Lam PYS, Wexler R, Humphrey WG, Shyu W-C, Grossman SJ. Preclinical pharmacokinetics and metabolism of apixaban, a potent and selective factor Xa inhibitor. Blood 2006; 108: 273a (Abstract# 910).
9. Frost C, Yu Z, Nepal S, Mosqueda-Garcia R, Shenker A. Apixaban, an oral direct, factor Xa inhibitor: Single-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost 2007; 5:(Suppl. 2): P-M-665.
10. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-75.
11. On behalf of the Botticelli investigators, the writing committee, Büller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-8.
12. Wong PC, Crain EJ, Watson CA, Jiang X, Hua J, Bostwick JS, Ogletree ML, Schumacher WA, Rehfuss R. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits. J Cardiovasc Pharmacol 2007; 49: 316-24.
13. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.
14. 12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 2008; 19: 125-33.
15. Wong PC, Crain EJ, Knabb RM, Meade RP, Quan ML, Watson CA, Wexler RR, Wright MR, Slee AM. Nonpeptide factor Xa inhibitors: II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther 2000; 295: 212-8.
16. Wong PC, Crain EJ, Watson CA, Zaspel AM, Wright MR, Lam PY, Pinto DJP, Wexler RR, Knabb RM. Nonpeptide factor Xa inhibitors III: Effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther 2002; 303: 993-1000.
17. Daykin HJ, Sturgeon SA, Jones C, Wright CE. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat. Thromb Res 2006; 118: 755-62.
18. Feuerstein GZ, Patel A, Toomey JR, Bugelski P, Nichols AJ, Church WR, Valocik R, Koster P, Baker A, Blackburn MN. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol 1999; 19: 2554-62.
19. Hong TT, Huang J, Driscoll E, Lucchesi BR. The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study). J Cardiovasc Pharmacol 2005;46: 526-33.
20. Wong PC, Crain EJ, Watson CA, Wexler RR, Lam PY, Quan ML, Knabb RM. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/ or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. J Thromb Thrombolysis 2007; 24: 43-51.
21. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nyström P, Bylock A; ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomised controlled trial. Lancet 2003; 362: 789-97.
22. Boudes PF. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemp Clin Trials 2006; 27: 432-40.
23. Bassand JP, Richard-Lordereau I, Cadroy Y. Efficacy and safety of fondaparinux in patients with acute coronary syndromes. Expert Rev Cardiovasc Ther 2007; 5: 1013-26.